resource source identifier antibodies rabbit polyclonal anti tdp 43 c terminal proteintech  (Proteintech)

Journal: bioRxiv

Article Title: Differential TDP-43 interactomes between the cortex and cerebellum in the mouse

doi: 10.64898/2026.01.16.699854

Figure Lengend Snippet: TDP-43 interactors differ between the cortex and cerebellum. (a) Antibodies raised to both the N (Abcam, #ab225710) and C (Proteintech #12892-1-AP) terminal of TDP-43 successfully pulled down TDP-43 from the nuclear fraction of both cortex and cerebellum samples. The C terminal antibody also successfully pulled down TDP-43 from the cytoplasmic fraction, albeit to a lesser extent. In contrast, no clear band was visible in cytoplasmic pull-downs using the N terminal antibody. IP: immunoprecipitation, FT: flow through. (b) Number of TDP-43 interactors identified, and their distribution across the various brain regions and cell fractions. While there were some overlaps between the cortex and cerebellum, there was marked differences in both nuclear and cytoplasmic interactors

Article Snippet: Samples were fractionated as described above then incubated with rabbit polyclonal N-terminal antibody (Abcam #ab225710) or rabbit polyclonal C-terminal antibody (Proteintech #12892-1-AP) coupled to Protein G Dynabeads (ThermoFisher, #10003D) at 4°C overnight (5μg/ml for nuclear fraction and 20μg/ml for cytoplasmic fraction).

Techniques: Immunoprecipitation

Journal: Neurotherapeutics

Article Title: Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS

doi: 10.1016/j.neurot.2025.e00737

Figure Lengend Snippet: I.t. delivery of E6 antibody improved motor performance and reduced TDP-43 proteinopathy in the lumbar spinal cord caused by infusion of ALS-CSF. (a) Gait analysis at day 14 post pump implantation evaluating the stride length (in millimeters) of hind limbs (PBS ​= ​50.07, E6 ​= ​56.66; p-value ​= ​0.0207) and fore limbs (PBS ​= ​51.53, E6 ​= ​57.35; p-value ​= ​0.0431) of ALS-CSF infused mice (n ​= ​8 mice per condition; circle ​= ​male, square ​= ​female) treated i.t. with E6 antibody or equal volume of PBS. Two-way ANOVA followed by Tukey's multiple comparisons test. (b) Representative single-channel and merged images of TDP-43 localization in the lumbar spinal cord ventral horn neurons using rabbit polyclonal antibody against TDP-43 ​C-Terminal (TDP-43, red; NeuN, green; Hoechst, blue). Arrowheads highlight cells showing depleted nuclear signal of TDP-43 after ALS-CSF infusion and restored nuclear TDP-43 signal after E6 treatment. Scale bar: 50 ​μm. (c) Quantification of nuclear to cytoplasmic ratio of TDP-43 signal in ≥250 ​μm 2 NeuN ​+ ​neurons (n ​= ​3–4 mice per condition). Data are represented as mean ​± ​SEM (PBS ​= ​1.051 ​± ​0.0295, E6 ​= ​1.108 ​± ​0.0194; p ​= ​0.0762). Unpaired one-tailed t -test. (d) Quantification of ≥250 ​μm 2 NeuN ​+ ​cells per hemisection (ventral horn) of the lumbar spinal cord (n ​= ​3 mice per condition). Data are represented as mean ​± ​SEM (PBS ​= ​27.09 ​± ​1.177, E6 ​= ​30.37 ​± ​1.281; p-value ​= ​0.0373). Paired one-tailed t -test. ∗p ​≤ ​0.05.

Article Snippet: Anti-TDP-43 , Rabbit polyclonal , Proteintech , 12892-1-AP , 1:500 , 1:1000 , RT/4 °C , 16.

Techniques: One-tailed Test

Journal: Neurotherapeutics

Article Title: Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS

doi: 10.1016/j.neurot.2025.e00737

Figure Lengend Snippet: I.c.v. delivery of E6 antibody reduced TDP-43 proteinopathy. (a) Representative single-channel and merged images of TDP-43 localization using a rabbit polyclonal antibody against TDP-43 ​C-Terminal on brain (motor cortex) tissues (TDP-43, red; NeuN, green; Hoechst, blue). Dotted line circles the nucleus. Arrowheads point to TDP-43 cytoplasmic inclusions. Scale bar: 10 ​μm. (b) Quantification of nuclear to cytoplasmic ratio of TDP-43 signal (n ​= ​4–5 mice per condition; NALS-CSF ​= ​4.003 ​± ​0.216, ALS-CSF ​+ ​PBS ​= ​2.816 ​± ​0.146, ALS-CSF ​+ ​E6 ​= ​3.71 ​± ​0.148, ALS-CSF ​+ ​CTR Ab ​= ​2.9 ​± ​0.162). One-way ANOVA followed by Tukey's multiple comparisons test. (c) Representative blots and quantifications of human TDP-43 in soluble and insoluble fractions of brain cortex lysates (n ​= ​4–5 mice per condition). Data are shown as fold of NALS-CSF (Soluble: ALS-CSF ​+ ​PBS ​= ​1.037 ​± ​0.031, ALS-CSF ​+ ​E6 ​= ​1.122 ​± ​0.02, ALS-CSF ​+ ​CTR Ab ​= ​0.962 ​± ​0.013; Insoluble: ALS-CSF ​+ ​PBS ​= ​1.012 ​± ​0.016, ALS-CSF ​+ ​E6 ​= ​0.948 ​± ​0.007, ALS-CSF ​+ ​CTR Ab ​= ​0.977 ​± ​0.01). One-way ANOVA by Tukey's multiple comparison test. Samples were run on the same gel but were noncontiguous. Total transferred proteins (TTP) were used as loading reference. (d) Count of ≥250 ​μm 2 NeuN+ and ChAT ​+ ​cells per hemisection of the ventral horns of the lumbar spinal cord (n ​= ​3–5 mice per condition; NALS-CSF ​= ​21.11 ​± ​0.588, ALS-CSF ​+ ​PBS ​= ​17.81 ​± ​1.056, ALS-CSF ​+ ​E6 ​= ​22.96 ​± ​1.137, ALS-CSF ​+ ​CTR Ab ​= ​16.81 ​± ​0.281). One-way ANOVA followed by Tukey's multiple comparisons test. All data are expressed as mean ​± ​SEM. ∗p ​≤ ​0.05, ∗∗p ​≤ ​0.01, ∗∗∗p ​≤ ​0.001.

Article Snippet: Anti-TDP-43 , Rabbit polyclonal , Proteintech , 12892-1-AP , 1:500 , 1:1000 , RT/4 °C , 16.

Techniques: Comparison